Overview

Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

Status:
Completed
Trial end date:
2020-06-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of 5% tavilermide and 1% tavilermide ophthalmic solutions compared with placebo ophthalmic solution in treating the signs and symptoms of dry eye.
Phase:
Phase 3
Details
Lead Sponsor:
Mimetogen Pharmaceuticals USA, Inc.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions